Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment

We analysed the hepatitis B virus (HBV) core‐promoter (CP) and precore (PC) regions before, during and after interferon treatment in young Caucasian cancer survivors who had acquired HBV infection during chemotherapy for malignancies. Fourteen patients with chronic hepatitis B [hepatitis B e antigen (HBeAg) /HBV‐DNA positive] received α‐2a interferon (IFN), 5 MU/m2 t.i.w. for 12 months. HBV CP and PC region sequences were analysed following polymerase chain reaction (PCR) amplification. Sera from responders were studied at: T0 (before starting IFN), T1 [at alanine aminotransferase (ALT) peak preceding HBeAg seroconversion], T2 (at ALT normalization), T3 (at end of IFN) and T4 (at one year after IFN) and in nonresponders at time points T0, T3 and T4. Amplified HBV‐DNA was cloned and sequenced automatically. Six of 14 patients (43%) responded to IFN treatment. Five of the six (83%) responders displayed the double CP mutation A1762T/G1764A always in association with a T1753C change. None of the nonresponders showed these mutations at any time point. The G1896A change creating the PC stop codon mutation was never detected in any of the patients. In our cancer survivors, IFN‐induced HBeAg/anti‐HBe seroconversion appeared to correlate with CP mutations and was not influenced by previous chemotherapy. These mutations in addition to low HBV DNA levels and elevated ALT can be considered favourable factors of response to IFN‐induced anti‐HBe seroconversion.

[1]  D. Blondin,et al.  Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B , 2000 .

[2]  W. Yeo,et al.  Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: Precore/core mutations may play an important role , 2000, Journal of medical virology.

[3]  D. Blondin,et al.  Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B , 2000, Hepatology.

[4]  L. Adinolfi,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Dual or Single Hepatitis B and C Virus Infections in Childhood Cancer Survivors: Long-Term Follow-Up and Effect of Interferon Treatment , 2016 .

[5]  S. Günther,et al.  Hepatitis B virus genomes from long-term immunosuppressed virus carriers are modified by specific mutations in several regions. , 1999, The Journal of general virology.

[6]  M. Shindo,et al.  The clinical significance of core promoter and precore mutations during the natural course and interferon therapy in patients with chronic hepatitis B , 1999, American Journal of Gastroenterology.

[7]  H. Trübel,et al.  Mutations in the basic core promotor and the precore region of hepatitis b virus and their selection in children with fulminant and chronic hepatitis B , 1999, Hepatology.

[8]  C. Hannoun,et al.  Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. , 1999, The Journal of infectious diseases.

[9]  A. Lok,et al.  Different hepatitis b virus genotypes are associated with different mutations in the core promoter and precore regions during hepatitis B e antigen seroconversion , 1999, Hepatology.

[10]  J. Ou,et al.  Mechanism of Suppression of Hepatitis B Virus Precore RNA Transcription by a Frequent Double Mutation , 1999, Journal of Virology.

[11]  T. Liang,et al.  Naturally Occurring Mutations Define a Novel Function of the Hepatitis B Virus Core Promoter in Core Protein Expression , 1998, Journal of Virology.

[12]  G. Norkrans,et al.  Mutation of nucleotide 1,762 in the core promoter region during hepatitis B e seroconversion and its relation to liver damage in hepatitis B e antigen carriers , 1998, Journal of medical virology.

[13]  S. Günther,et al.  Wild-type levels of pregenomic RNA and replication but reduced pre-C RNA and e-antigen synthesis of hepatitis B virus with C(1653) --> T, A(1762) --> T and G(1764) --> A mutations in the core promoter. , 1998, The Journal of general virology.

[14]  T. Fujioka,et al.  Sequential analyses of the mutations in the core upstream and precore regions of hepatitis B virus genome in anti‐HBe positive‐carriers developing acute exacerbation , 1997, Journal of medical virology.

[15]  A. Kidd,et al.  Hepatitis B virus X gene 1751 to 1764 mutations: implications for HBeAg status and disease. , 1997, The Journal of general virology.

[16]  J. Wands,et al.  Posttranscriptional regulation of hepatitis B virus replication by the precore protein , 1997, Journal of virology.

[17]  S. Günther,et al.  Type, prevalence, and significance of core promoter/enhancer II mutations in hepatitis B viruses from immunosuppressed patients with severe liver disease , 1996, Journal of virology.

[18]  T. Liang,et al.  Two core promotor mutations identified in a hepatitis B virus strain associated with fulminant hepatitis result in enhanced viral replication. , 1996, The Journal of clinical investigation.

[19]  M. Chen,et al.  Effects of a naturally occurring mutation in the hepatitis B virus basal core promoter on precore gene expression and viral replication , 1996, Journal of virology.

[20]  H. Will,et al.  Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation , 1996, Hepatology.

[21]  N. Enomoto,et al.  Mutations in the core promoter region of hepatitis B virus in patients with chronic hepatitis B , 1996, Journal of medical virology.

[22]  H. Okamoto,et al.  Hepatitis B Virus Strains with Mutations in the Core Promoter in Patients with Fulminant Hepatitis , 1995, Annals of Internal Medicine.

[23]  Mark George Thomas,et al.  Genomic variations in the hepatitis B core gene: a possible factor influencing response to interferon alfa treatment. , 1995, Gastroenterology.

[24]  F Tsuda,et al.  Hepatitis B virus with mutations in the core promoter for an e antigen-negative phenotype in carriers with antibody to e antigen , 1994, Journal of virology.

[25]  J. Hoofnagle,et al.  Classification of chronic hepatitis: Diagnosis, grading and staging , 1994, Hepatology.

[26]  P. Marcellin,et al.  Treatment of chronic viral hepatitis. , 1994, Bailliere's clinical gastroenterology.

[27]  E. Sagnelli,et al.  Treatment of chronic hepatitis B in children with prednisone followed by alfa-interferon: a controlled randomized study. , 1994, Journal of hepatology.

[28]  M. Brunetto,et al.  Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. , 1993, Gastroenterology.

[29]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[30]  J. Wands,et al.  Association of hepatitis B viral precore mutations with fulminant hepatitis B in Japan. , 1991, Virology.

[31]  H. Will,et al.  Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  H. Thomas,et al.  Treatment of hepatitis B virus infection with interferon. Factors predicting response to interferon. , 1991, Journal of hepatology.

[33]  T. Chan,et al.  Hepatitis B infection in patients with lymphomas , 1990, Hematological oncology.

[34]  M. Rugge,et al.  Long-term outcome of chronic type B hepatitis in patients who acquire hepatitis B virus infection in childhood. , 1990, Gastroenterology.

[35]  H. Will,et al.  A new hepatitis B virus strain in patients with severe anti-HBe positive chronic hepatitis B. , 1990, Journal of hepatology.

[36]  J. Lau,et al.  α-Interferon treatment in Chinese patients with chronic hepatitis B , 1990 .

[37]  H. Thomas,et al.  MUTATION PREVENTING FORMATION OF HEPATITIS B e ANTIGEN IN PATIENTS WITH CHRONIC HEPATITIS B INFECTION , 1989, The Lancet.

[38]  C. Chu,et al.  The development of cirrhosis in patients with chronic type B hepatitis: A prospective study , 1988, Hepatology.

[39]  Roger Williams,et al.  FULMINANT HEPATITIS B IN SUCCESSIVE FEMALE SEXUAL PARTNERS OF TWO ANTI-HBe-POSITIVE MALES , 1986, The Lancet.

[40]  J. Hoofnagle,et al.  Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. , 1982, Annals of internal medicine.

[41]  Lu-Yu Hwang,et al.  HEPATOCELLULAR CARCINOMA AND HEPATITIS B VIRUS A Prospective Study of 22 707 Men in Taiwan , 1981, The Lancet.